Abstract
Purpose: Chronic Pelvic Pain Syndromes (CPPS) affect an important percentage (5–9%) of the patients in urology practice; however there has been no consensus as to how the treatment should be planned in these patients. The purpose of our study is to evaluate the effectiveness of terazosine in the treatment of CPPS patients. Materials and methods: In our outpatient department, between May 1997 and October 1999, 91 patients were diagnosed as CPPS. These patients were first evaluated by Prostatitis Symptom Score Index (PSSI) and then randomized into two treatment groups. The first group received 2 mg/day terazosine (47 patients), and the others received placebo (42 patients). After three months of treatment, 69 patients came back for the control visit (terazosine 39, placebo 30). They were reexamined by PSSI and their results were evaluated by Wilcoxon analysis. Results: Before the treatment PSSI of the 39 patients who received terazosine were 9.61 ± 1.61, after the treatment they were 6.25 ± 1.60. For the placebo group, PSSI values before the treatment were 9.27 ± 1.88, after the treatment they were 8.81 ± 2.66. In the terazosine group, the difference between the pretreatment and post treatment PSSI values was statistically significant (p = 0.0002). In the placebo group, on the other hand, this difference was statistically insignificant (p = 0.701). After the treatment, the difference between the terazosine and placebo groups was also statistically significant (p = 0.001). In the terazosine group (as the recommendation was to take the medication at night) postural hypotension did not develop. Conclusion: Terazosine was effective for the treatment of CPPS. However it was concluded that three months of treatment was insufficient.
Similar content being viewed by others
References
Meares EM, Jr. Prostatitis and related disorders. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, Jr, eds. Campbell' Urology, 6th edn. Philadelphia: WB Saunders, 1998, pp. 615–630.
Nickel JC, Nyberg LM, Hennenfent M et al. Research guidelines for chronic prostatitis: consensus report from the first national prostatitis collaborative network. Urology 1999; 54: 229–233.
Moon TD. Questionnaire survey of urologists and primary care physicians' diagnostic and treatment practices for prostatitis. Urology 1997; 50: 543–547.
Collins MM, Stafford RS, O'leary MP et al. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Urology 1999; 53: 921–925.
Rosette JJMCH, Hubregtse MR, Meuleman EJH et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; 41(4): 301–307.
Neal DE, Jr, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994; 43(4): 460–465.
Leskinen M, Lukkarinen O, Marttila T. Effects of finasteride in patients with inflamatory chronic pelvic pain syndrome: a double-blind, placebo-controlled pilot study. Urology 1999; 53: 502–505.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gül, O., Eroğlu, M. & Özok, U. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol 32, 433–436 (2001). https://doi.org/10.1023/A:1017504830834
Issue Date:
DOI: https://doi.org/10.1023/A:1017504830834